JP2002518384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002518384A5 JP2002518384A5 JP2000554719A JP2000554719A JP2002518384A5 JP 2002518384 A5 JP2002518384 A5 JP 2002518384A5 JP 2000554719 A JP2000554719 A JP 2000554719A JP 2000554719 A JP2000554719 A JP 2000554719A JP 2002518384 A5 JP2002518384 A5 JP 2002518384A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- aryl
- alkoxy
- haloaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 25
- 229910052799 carbon Inorganic materials 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- 125000003106 haloaryl group Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 125000001475 halogen functional group Chemical group 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000006720 (C1-C6) alkyl (C6-C10) aryl group Chemical group 0.000 description 2
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000005027 hydroxyaryl group Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical compound NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8968298P | 1998-06-17 | 1998-06-17 | |
| US60/089,682 | 1998-06-17 | ||
| PCT/US1999/013677 WO1999065894A1 (en) | 1998-06-17 | 1999-06-16 | Macrocyclic analogs and methods of their use and preparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002518384A JP2002518384A (ja) | 2002-06-25 |
| JP2002518384A5 true JP2002518384A5 (enExample) | 2009-10-01 |
| JP4454151B2 JP4454151B2 (ja) | 2010-04-21 |
Family
ID=22219026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000554719A Expired - Lifetime JP4454151B2 (ja) | 1998-06-17 | 1999-06-16 | 大環状類似体及びそれらの使用並びに調製方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US6214865B1 (enExample) |
| EP (4) | EP2272839B1 (enExample) |
| JP (1) | JP4454151B2 (enExample) |
| KR (1) | KR100798600B1 (enExample) |
| CN (1) | CN1216051C (enExample) |
| AT (1) | ATE502932T1 (enExample) |
| AU (1) | AU762998B2 (enExample) |
| BE (1) | BE2011C028I2 (enExample) |
| BR (1) | BRPI9911326B8 (enExample) |
| CA (3) | CA2632433C (enExample) |
| CY (2) | CY1111516T1 (enExample) |
| DE (2) | DE122011100031I1 (enExample) |
| DK (1) | DK1087960T3 (enExample) |
| FR (1) | FR11C0038I2 (enExample) |
| HU (1) | HU227912B1 (enExample) |
| IL (1) | IL139960A0 (enExample) |
| LU (1) | LU91854I2 (enExample) |
| NO (5) | NO328280B1 (enExample) |
| NZ (1) | NZ508597A (enExample) |
| PT (1) | PT1087960E (enExample) |
| WO (1) | WO1999065894A1 (enExample) |
| ZA (1) | ZA200007159B (enExample) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2632433C (en) * | 1998-06-17 | 2012-02-07 | Eisai R & D Management Co., Ltd. | Methods for preparing macrocyclic analogs and intermediates for preparing same |
| US8097648B2 (en) * | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| DE10037310A1 (de) | 2000-07-28 | 2002-02-07 | Asta Medica Ag | Neue Indolderivate und deren Verwendung als Arzneimittel |
| WO2003072754A2 (en) * | 2002-02-27 | 2003-09-04 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
| WO2003082268A2 (en) | 2002-03-22 | 2003-10-09 | Eisai Co. Ltd | Hemiasterlin derivatives and uses thereof in the treatment of cancer |
| US20050075395A1 (en) * | 2003-05-28 | 2005-04-07 | Gary Gordon | Continuous dosing regimen |
| CA2526385C (en) * | 2003-05-29 | 2008-07-22 | Abbott Laboratories | Continuous dosing regimen with abt-751 |
| WO2005011589A2 (en) * | 2003-07-29 | 2005-02-10 | Eisai Co., Ltd. | Drug delivery methods and devices |
| KR101434673B1 (ko) * | 2004-06-03 | 2014-08-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 ｂ 유사체의 제조를 위한 중간체 |
| CN108997267A (zh) * | 2004-06-03 | 2018-12-14 | 卫材R&D管理有限公司 | 用于制备软海绵素b的类似物的中间体 |
| US20060045846A1 (en) * | 2004-08-30 | 2006-03-02 | Horstmann Thomas E | Reagents and methods for labeling terminal olefins |
| JP2008522623A (ja) * | 2004-12-09 | 2008-07-03 | エーザイ株式会社 | ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング |
| EP2578576B9 (en) * | 2007-10-03 | 2016-09-14 | Eisai R&D Management Co., Ltd. | Intermediates for the synthesis of halichondrin B analogs |
| RU2517167C2 (ru) * | 2008-04-04 | 2014-05-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аналоги галихондрина в |
| PE20120923A1 (es) | 2009-03-30 | 2012-08-27 | Eisai Randd Man Co Ltd | Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo |
| RU2476216C1 (ru) * | 2009-03-30 | 2013-02-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Липосомальная композиция |
| WO2010113983A1 (ja) | 2009-03-30 | 2010-10-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
| WO2010119890A1 (ja) * | 2009-04-14 | 2010-10-21 | 日産化学工業株式会社 | テトラヒドロピラン化合物の製造方法およびその中間体 |
| CA2771403C (en) | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| US8203010B2 (en) | 2010-01-26 | 2012-06-19 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
| EP2686441B1 (en) | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
| WO2012147900A1 (en) | 2011-04-28 | 2012-11-01 | Eisai R&D Management Co., Ltd. | Microreactor process for halichondrin b analog synthesis |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| CA2857385A1 (en) | 2011-11-30 | 2013-06-06 | Alphora Research Inc. | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
| JP2015501818A (ja) | 2011-12-16 | 2015-01-19 | アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． | ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法 |
| IN2014MN01521A (enExample) * | 2011-12-29 | 2015-05-01 | Alphora Res Inc | |
| CN104334562A (zh) * | 2012-03-30 | 2015-02-04 | 阿方拉研究股份有限公司 | 用于制备软海绵素b的大环c1-酮类似物的合成方法及其中有用的中间体 |
| AU2013353745A1 (en) | 2012-12-04 | 2015-06-11 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of breast cancer |
| US9650397B2 (en) | 2013-05-15 | 2017-05-16 | Alphora Research Inc. | 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof |
| CN105338977B (zh) | 2013-06-26 | 2018-10-16 | 卫材R&D管理有限公司 | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 |
| WO2015000070A1 (en) | 2013-07-03 | 2015-01-08 | Alphora Research Inc. | Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups |
| CN103483352A (zh) * | 2013-10-18 | 2014-01-01 | 李友香 | 抗肿瘤的药用原料药 |
| CA2929084C (en) | 2013-11-04 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin b |
| BR112016012237B1 (pt) | 2013-12-06 | 2023-02-07 | Eisai R&D Management Co., Ltd | Métodos úteis na síntese de análogos de halicondrina b |
| CN104860978A (zh) * | 2014-02-20 | 2015-08-26 | 正大天晴药业集团股份有限公司 | 软海绵素b类似物的合成中间体 |
| TW201617326A (zh) | 2014-03-06 | 2016-05-16 | Ａｌｐｈｏｒａ研發股份有限公司 | （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物 |
| WO2015183961A1 (en) | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd | Use of eribulin in the treatment of cancer |
| WO2016003975A1 (en) | 2014-06-30 | 2016-01-07 | President And Fellows Of Harvard College | Synthesis of halichondrin analogs and uses thereof |
| EP3187491A4 (en) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US10208058B2 (en) | 2014-09-09 | 2019-02-19 | Cipla Limited | Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof |
| CN105713031B (zh) * | 2014-12-05 | 2021-05-07 | 正大天晴药业集团股份有限公司 | 一种用于制备艾日布林的中间体及其制备方法 |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| MX386547B (es) * | 2015-03-04 | 2025-03-19 | Merck Sharp & Dohme | Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer. |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| WO2016176560A1 (en) | 2015-04-30 | 2016-11-03 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
| MX392296B (es) * | 2015-05-07 | 2025-03-24 | Eisai R&D Man Co Ltd | Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina. |
| US10597401B2 (en) | 2015-05-08 | 2020-03-24 | Albany Molecular Research, Inc. | Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| MX377663B (es) | 2016-02-12 | 2025-03-11 | Eisai R&D Man Co Ltd | Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados. |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| CN109415383A (zh) * | 2016-05-26 | 2019-03-01 | 雷迪博士实验室有限公司 | 制备艾日布林的方法及其中间体 |
| US11136335B2 (en) | 2016-06-30 | 2021-10-05 | Eisai R&D Management Co., Ltd. | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof |
| SG11201902974PA (en) | 2016-10-14 | 2019-05-30 | Merck Sharp & Dohme | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
| JP6978758B2 (ja) | 2016-11-11 | 2021-12-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | パラジウム媒介ケトール化 |
| BR112019010494A2 (pt) * | 2016-11-23 | 2019-09-17 | Dr Reddys Laboratories Ltd | processo para a preparação de eribulina e intermediários do mesmo |
| KR101991710B1 (ko) | 2017-12-14 | 2019-06-21 | 연성정밀화학(주) | 에리불린 메실산염의 제조 중간체 및 그의 제조방법 |
| KR101880939B1 (ko) | 2017-01-02 | 2018-08-17 | 연성정밀화학(주) | 에리불린 메실산염의 제조 중간체 및 그의 제조방법 |
| CN110139866B (zh) * | 2017-01-02 | 2022-05-17 | 研成精密化学株式会社 | 用于制备甲磺酸艾日布林的中间体以及制备其的方法 |
| CN108341738B (zh) * | 2017-01-24 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 用于制备艾日布林的方法及其中间体 |
| CN108341828B (zh) * | 2017-01-24 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 用于制备艾日布林的方法及其中间体 |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| US9938288B1 (en) | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
| SI3606928T1 (sl) | 2017-04-05 | 2023-02-28 | President And Fellows Of Harvard College | Makrociklična spojina in njene uporabe |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| HUE061306T2 (hu) | 2017-07-06 | 2023-06-28 | Harvard College | Halikondrinok szintézise |
| US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
| US20190046513A1 (en) | 2017-08-10 | 2019-02-14 | Huya Bioscience International, Llc | Combination therapies of hdac inhibitors and tubulin inhibitors |
| CN109694379B (zh) * | 2017-10-24 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 用于制备艾日布林的中间体及其制备方法 |
| WO2019093776A1 (ko) | 2017-11-09 | 2019-05-16 | 연성정밀화학(주) | 에리불린 메실산염의 제조 중간체 및 그의 제조방법 |
| CN111566113B (zh) | 2017-11-15 | 2024-01-09 | 哈佛大学的校长及成员们 | 大环化合物及其用途 |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| US11008296B2 (en) | 2017-11-21 | 2021-05-18 | Natco Pharma Limited | Intermediates for the preparation of eribulin thereof |
| MX2020006945A (es) | 2018-01-03 | 2020-11-09 | Eisai R&D Man Co Ltd | Reaccion de prins y compuestos utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos. |
| WO2019211877A1 (en) | 2018-05-03 | 2019-11-07 | Cipla Limited | Process for the preparation of macrocyclic ketone analogs of halichondrin b |
| WO2020008382A1 (en) * | 2018-07-04 | 2020-01-09 | Dr. Reddy’S Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
| CN112437775A (zh) * | 2018-07-20 | 2021-03-02 | 雷迪博士实验室有限公司 | 用于制备艾日布林及其中间体的纯化方法 |
| WO2020075027A1 (en) * | 2018-10-09 | 2020-04-16 | Dr. Reddy's Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
| WO2020110146A1 (en) * | 2018-11-28 | 2020-06-04 | Natco Pharma Limited | Process for the preparation of high pure eribulin and its mesylate salt |
| CN113766914B (zh) | 2018-12-20 | 2024-02-13 | 美商奥润沙公司 | 戊烷脒的类似物和其用途 |
| US11447499B2 (en) | 2019-06-14 | 2022-09-20 | Rk Pharma Inc. | Process for the preparation of eribulin mesylate intermediate |
| US12247239B2 (en) | 2019-06-21 | 2025-03-11 | Council Of Scientific & Industrial Research | Chemo-enzymatic process for the preparation of homopropargylic alcohol |
| ES3075649T3 (en) | 2019-07-26 | 2026-08-06 | Eisai R&D Man Co Ltd | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2021090062A1 (en) | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
| CN113135876B (zh) * | 2020-01-16 | 2024-05-17 | 南通诺泰生物医药技术有限公司 | 艾日布林及其中间体的制备方法 |
| JP7821733B2 (ja) * | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| KR102377262B1 (ko) | 2020-05-11 | 2022-03-22 | 연성정밀화학(주) | 결정성 에리불린 염 |
| IL279168B (en) | 2020-12-02 | 2022-04-01 | Finetech Pharmaceutical Ltd | A process for the preparation of eribulin |
| CN113354659B (zh) | 2021-06-08 | 2022-04-08 | 江苏慧聚药业股份有限公司 | 甲磺酸艾日布林的合成 |
| MX2024000893A (es) * | 2021-07-22 | 2024-02-06 | Shanghai Senhui Medicine Co Ltd | Farmaco conjugado de un derivado de eribulina. |
| WO2023212746A2 (en) * | 2022-04-30 | 2023-11-02 | William Marsh Rice University | A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b |
| AU2024209545A1 (en) * | 2023-01-17 | 2025-08-07 | Systimmune, Inc. | Conjugate of eribulin drug |
| EP4725969A1 (en) | 2023-06-09 | 2026-04-15 | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. | Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof |
| CN118834221B (zh) * | 2023-08-08 | 2025-10-21 | 浙江星月药物科技有限公司 | 一种软海绵素b类似物 |
| CN122349614A (zh) | 2023-10-13 | 2026-07-07 | 卫材R&D管理有限公司 | 抗体-药物缀合物代谢物 |
| WO2025106586A1 (en) * | 2023-11-13 | 2025-05-22 | Luxvitae Therapeutics Inc. | Macrocyclic ketone compounds and applications thereof |
| WO2025228172A1 (zh) * | 2024-04-28 | 2025-11-06 | 上海拓济医药有限责任公司 | 艾日布林衍生物及其抗体药物偶联物和医药用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338865A (en) * | 1992-03-12 | 1994-08-16 | President And Fellows Of Harvard College | Synthesis of halichondrin B and norhalichondrin B |
| US5436238A (en) | 1992-03-12 | 1995-07-25 | President And Fellows Of Harvard College | Halichondrins and related compounds |
| GB9206244D0 (en) * | 1992-03-23 | 1992-05-06 | Pharma Mar Sa | Cytotoxic compound from a marine sponge |
| US5426194A (en) * | 1993-01-19 | 1995-06-20 | Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Isolation and structure of Halistatin 1 |
| CA2632433C (en) * | 1998-06-17 | 2012-02-07 | Eisai R & D Management Co., Ltd. | Methods for preparing macrocyclic analogs and intermediates for preparing same |
| US6653341B1 (en) * | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| KR101434673B1 (ko) | 2004-06-03 | 2014-08-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 ｂ 유사체의 제조를 위한 중간체 |
| EP2578576B9 (en) * | 2007-10-03 | 2016-09-14 | Eisai R&D Management Co., Ltd. | Intermediates for the synthesis of halichondrin B analogs |
| CN101910180A (zh) * | 2007-11-16 | 2010-12-08 | 卫材R&D管理有限公司 | 用于软海绵素b类似物合成的新颖中间体和用于该中间体的新颖脱磺酰化反应 |
| RU2517167C2 (ru) * | 2008-04-04 | 2014-05-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Аналоги галихондрина в |
| US8203010B2 (en) * | 2010-01-26 | 2012-06-19 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
-
1999
- 1999-06-16 CA CA2632433A patent/CA2632433C/en not_active Expired - Lifetime
- 1999-06-16 WO PCT/US1999/013677 patent/WO1999065894A1/en not_active Ceased
- 1999-06-16 BR BRPI9911326A patent/BRPI9911326B8/pt not_active IP Right Cessation
- 1999-06-16 CA CA2755266A patent/CA2755266C/en not_active Expired - Lifetime
- 1999-06-16 PT PT99928746T patent/PT1087960E/pt unknown
- 1999-06-16 DE DE201112100031 patent/DE122011100031I1/de active Pending
- 1999-06-16 CN CN99809658XA patent/CN1216051C/zh not_active Expired - Lifetime
- 1999-06-16 EP EP10010773A patent/EP2272839B1/en not_active Expired - Lifetime
- 1999-06-16 EP EP10010774A patent/EP2272840B1/en not_active Expired - Lifetime
- 1999-06-16 DK DK99928746.9T patent/DK1087960T3/da active
- 1999-06-16 US US09/334,488 patent/US6214865B1/en not_active Expired - Lifetime
- 1999-06-16 AU AU45739/99A patent/AU762998B2/en not_active Expired
- 1999-06-16 NZ NZ508597A patent/NZ508597A/en not_active IP Right Cessation
- 1999-06-16 AT AT99928746T patent/ATE502932T1/de active
- 1999-06-16 CA CA002335300A patent/CA2335300C/en not_active Expired - Lifetime
- 1999-06-16 JP JP2000554719A patent/JP4454151B2/ja not_active Expired - Lifetime
- 1999-06-16 EP EP99928746A patent/EP1087960B1/en not_active Expired - Lifetime
- 1999-06-16 KR KR1020007014229A patent/KR100798600B1/ko not_active Expired - Lifetime
- 1999-06-16 DE DE69943296T patent/DE69943296D1/de not_active Expired - Lifetime
- 1999-06-16 IL IL13996099A patent/IL139960A0/xx active Protection Beyond IP Right Term
- 1999-06-16 HU HU0103357A patent/HU227912B1/hu active Protection Beyond IP Right Term
- 1999-06-16 EP EP10010772A patent/EP2277873B1/en not_active Expired - Lifetime
-
2000
- 2000-10-02 US US09/677,485 patent/US6365759B1/en not_active Expired - Lifetime
- 2000-12-04 ZA ZA200007159A patent/ZA200007159B/en unknown
- 2000-12-12 NO NO20006316A patent/NO328280B1/no not_active IP Right Cessation
-
2001
- 2001-04-26 US US09/843,617 patent/US6469182B1/en not_active Expired - Lifetime
-
2009
- 2009-10-26 NO NO20093217A patent/NO331183B1/no active Protection Beyond IP Right Term
-
2010
- 2010-08-12 US US12/855,412 patent/US8148554B2/en not_active Expired - Fee Related
-
2011
- 2011-06-01 CY CY20111100530T patent/CY1111516T1/el unknown
- 2011-08-12 CY CY2011010C patent/CY2011010I1/el unknown
- 2011-08-17 LU LU91854C patent/LU91854I2/fr unknown
- 2011-09-02 BE BE2011C028C patent/BE2011C028I2/fr unknown
- 2011-09-09 FR FR11C0038C patent/FR11C0038I2/fr active Active
- 2011-09-16 NO NO2011018C patent/NO2011018I1/no unknown
- 2011-12-14 NO NO2011026C patent/NO2011026I2/no unknown
-
2022
- 2022-06-03 NO NO2022019C patent/NO2022019I1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2221798C2 (ru) | Имидазонафтиридины, фармацевтическая композиция на их основе, способ стимуляции биосинтеза цитокина и промежуточные вещества | |
| JP2002543185A5 (enExample) | ||
| JP2001525411A5 (enExample) | ||
| JP2004525888A5 (enExample) | ||
| KR910006200A (ko) | 퀴논 유도체 및 약리학적 이용 | |
| RU2010106878A (ru) | Комбинация антимитотического агента и ингибитора аврора киназы как средство для лечения рака | |
| RU93043106A (ru) | Способ получения производных таксана, производные таксана, фармацевтическая композиция на их основе, способ лечения, производные оксазолидина и способ получения производных оксазолидина | |
| EP1492173A3 (en) | Light emitting device containing a rare earth complex as luminescent medium | |
| EP1826196A3 (en) | Vinyl ether compounds | |
| TR200102109T2 (tr) | Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod. | |
| JP2004531544A5 (enExample) | ||
| RU2004129766A (ru) | Флюоресцентный контрастирующий агент ближней инфракрасной области спектра и способ флуоресцентной томографии | |
| ATE471323T1 (de) | Purinderivate als antagonisten an purinergen rezeptoren | |
| JP2001523712A5 (enExample) | ||
| CO5580825A2 (es) | Derivados heterociclicos de glicinamida y su uso medico | |
| JP2009503110A5 (enExample) | ||
| JP2003506447A5 (enExample) | ||
| EP0350948A3 (en) | Porphyrin derivatives | |
| JP2004501093A5 (enExample) | ||
| KR920000335A (ko) | 영상제로서 거대환상 아미노포스폰산 착체의 용도 | |
| KR920004340A (ko) | 술폰아미드 유도체 | |
| KR860003242A (ko) | 5-플루오로우라실 유도체의 제조방법 | |
| KR960022508A (ko) | 모노아조 화합물 및 이를 사용하는 섬유 재료의 염색 또는 날염방법 | |
| RU2002109593A (ru) | Пентациклическое соединение таксана | |
| RU98122311A (ru) | Производные таксана, их получение и содержащие их композиции |